RFK Jr. Suggests FDA Overlook Unverified Peptides, According to Report

The Food and Drug Administration (FDA), under the leadership of Health Secretary Robert F. Kennedy Jr., is advancing plans to facilitate access to untested peptide drugs. These substances are popular among followers of Kennedy’s Make America Healthy Again movement. However, skeptically, FDA scientists have indicated that there is insufficient research to confirm the safety and effectiveness of these drugs, with potential risks involved.

An “Interim Access Policy” concerning peptides has been submitted for review to the White House, as per a recent posting on a government website associated with the Office of Management and Budget. While specific details of the proposed policy remain undisclosed, sources familiar with the matter have revealed to The Associated Press that it may grant the FDA “enforcement discretion” over specific peptide drugs. This measure would enable the agency to bypass current regulatory restrictions, thereby providing assurances to specialty pharmacies keen on producing these substances that they will not face agency repercussions.

The initiative coincides with the FDA’s ongoing reassessment of a dozen widely used, yet unproven, injectable peptide drugs. Following a review in 2023, FDA scientists concluded that these peptides lack substantial data on their safety and efficacy, leading to their removal from a list permitting production by specialty compounding pharmacies.

Concerns Over “Charlatans”

Despite the lack of credible evidence, these questionable drugs have gained traction, with vendors promoting them as solutions for enhancing physical appearance, boosting energy levels, and aiding injury recovery. These peptides have particularly resonated within the MAHA community, where numerous prominent figures advocate for peptide products. Kennedy himself, professing a strong affinity for these substances, has pledged to reverse what he describes as the FDA’s ongoing “war” against peptides.